Emily Klatte, MD
Epilepsy · Columbus, OHNPI 1548474406
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,355 of the $64,115 with a category attached, or 70.7%. Neurelis, Inc. accounts for 89.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $18,456 and has fallen 60.4% since, to $7,307 in 2025. Among epilepsy clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $525.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$57K
- Neuropace, Inc.$5K
- SK Life Science, Inc.$663
- Livanova USA, Inc.$298
- UCB, Inc.$256
- Sanofi$136
- plus $287 from 7 others
What the payments were for
- Consulting fees$5,8649%
- Speaking & faculty fees$45,35571%
- Travel & lodging$8,32413%
- Food & beverage$4,4727%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 73 | $57,190 |
| Neuropace, Inc. | 20 | $5,284 |
| SK Life Science, Inc. | 11 | $663 |
| Livanova USA, Inc. | 3 | $298 |
| UCB, Inc. | 4 | $256 |
| Sanofi | 1 | $136 |
| Eisai Inc. | 1 | $116 |
| Zimmer Biomet | 1 | $57 |
| Supernus Pharmaceuticals, Inc. | 3 | $35 |
| Catalyst Pharmaceuticals, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ceribell, Inc. | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$56,484
- RNS Neurostimulator Kit$3,852
- RNS System$948
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$226
- AUBAGIO$136
- Fycompa$116
How this compares
$64,115 in reported general payments places this provider in the 90th percentile of 21 epilepsy providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 38 | $307,397 |
| Lamictal XrLamotrigine | 34 | $105,276 |
| XcopriCenobamate | 64 | $100,074 |
| VimpatLacosamide | 86 | $95,155 |
| Rufinamide | 17 | $94,870 |
| AptiomEslicarbazepine Acetate | 38 | $90,879 |
| Keppra XrLevetiracetam | 56 | $82,292 |
| KeppraLevetiracetam | 32 | $62,314 |
| BriviactBrivaracetam | 18 | $42,168 |
| TopamaxTopiramate | 21 | $39,244 |
| Lacosamide | 156 | $33,024 |
| ValtocoDiazepam | 17 | $26,021 |
| NayzilamMidazolam | 18 | $23,391 |
| Clobazam | 138 | $20,397 |
| LamictalLamotrigine | 15 | $19,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat, Briviact, Nayzilam | $256 | $160,714122 claims |
| SK Life Science, Inc.Xcopri | $663 | $100,07464 claims |
| Neurelis, Inc.Valtoco | $57,190 | $26,02117 claims |
| Eisai Inc.Fycompa | $116 | $16,91114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 epilepsy providers in Ohio.
Other epilepsy in Columbus
- Danielle BeckerColumbus$1.6M
- Jason BispingColumbus$261K
- Jaysingh SinghColumbus$3K
- Bryan BergerColumbus$1K
- Angela ParsonsColumbus$484
- Sarita MaturuColumbus$280
- Nabil KhandkerColumbus$156
- Mohamad RahwanWest Chester$7K
- Neel FotedarCleveland$3K
- Luisa Londono-HurtadoCleveland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.